Published in Vaccine Weekly, June 28th, 2000
"In many instances, repeated administrations of adenoviral gene therapy vectors will be required to obtain therapeutic levels of the protein of interest," said Helene Haegel-Kronenberger and colleagues from Transgene S.A., France, Utrecht University and Tanox Pharmaceuticals, The Netherlands. "Re-administration of adenoviral vectors into immunocompetent hosts is hampered by the development of a neutralizing humoral response against adenoviral proteins. Transient immunosuppression of patients may be necessary to decrease or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.